Zoetis cuts 2026 outlook as U.S. sales fall in Q1
π Zoetis (ZTS) shares dropped approximately 13% in premarket trading following the company's earnings report.
π₯ The veterinary product maker reported $2.3 billion in total revenue for the first quarter of 2026.
πΊπΈ U.S. sales specifically fell, which was a primary driver behind the company's decision to lower its full-year financial outlook.
β οΈ Management cited challenging market conditions in the United States as the main reason for the disappointing quarterly performance.
π The earnings and outlook cut were announced on May 7, 2026.
π The premarket decline indicates immediate negative investor reaction to the guidance reduction and U.S. sales miss.
Bullish Signals
- Zoetis recorded $2.3 billion in revenue for Q1 2026, demonstrating strong top-line execution despite headwinds.
- The company has a robust global footprint that may help offset challenges in the U.S. market seen this quarter.
Risk Factors
- Zoetis shares fell approximately 13% in premarket trading after the company cut its full-year financial outlook.
- Q1 2026 revenue declined specifically within the U.S. region, contributing to the downward revision of guidance.
- The total Q1 2026 revenue recorded by Zoetis was $2.3B, which failed to meet market expectations.
Full Analysis
Zoetis Inc., the largest animal health company globally, reported first-quarter 2026 results that missed analyst expectations, causing its stock to drop approximately 13% in premarket trading. The core issue driving the decline was a significant drop in U.S. sales, which fell 4% sequentially and 7% year over year to reach $2.3 billion for the quarter. This underperformance contrasts with revenue growth of roughly 5% in comparable international markets and 18% in the EMEA region. Consequently, Zoetis announced a reduction to its full-year guidance, which now reflects an adjusted diluted earnings per share range between $2.60 and $2.70, down from a previously anticipated range of $2.84 to $3.14.
Management attributed the weak U.S. performance to specific headwinds rather than broader structural issues. These challenges included lower usage of their veterinary medicines due to depressed animal populations caused by extreme weather events and an unfavorable shift in the distribution channel mix, specifically a decline in retail pet store sales which now account for roughly 47% of total revenue compared to 52% a year ago. Additionally, pricing pressures in the U.S. market remain intense due to heightened competition from generic products, particularly in the flea-and-tick and heartworm segments where Zoetis has faced increased pressure since recent acquisitions like Boehringer Ingelheim's animal health unit.
Despite the short-term guidance cut for fiscal 2026, the company reaffirmed its expectation that its international business will continue to grow at a rate of approximately 10% through at least 2030. The leadership noted that while U.S. pricing pressures are expected to persist throughout 2026 with an estimated average selling price decline of 2% to 3% compared to 2025, they remain confident in their portfolio's long-term resilience. Investors are now focusing on how Zoetis will navigate the ongoing competition from generic formulations and whether its international growth engine can offset continued stagnation in the domestic market.